<DOC>
	<DOC>NCT00143520</DOC>
	<brief_summary>This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison.</brief_summary>
	<brief_title>Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 diabetes in male or female patients Between 18 and 75 years of age With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization Type 1 diabetics or type 2 diabetics currently on insulin therapy Patients unwilling or unable to discontinue their antidiabetic medication(s) History of ketoacidosis History of therapy with rosiglitazone, troglitazone, pioglitazone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Placebo and active control dose response study of rivoglitazone in type 2 diabetics</keyword>
</DOC>